First AD

Second AD

Scott Kopetz, MD, PhD, FACP, Deputy Chair for Translational Research, Department of Gastrointestinal (GI) Medical Oncology, Professor, Department of Gastrointestinal (GI) Medical Oncology and Leader, Department of Cancer Center Support Grant, GI Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss how ctDNA assays have improved in MRD detection in CRC.

The Evolution of ctDNA Assays in CRC

Colorectal Cancer

 Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

OncLive News Network®

® video programs provide lively discussions, insights, and expert perspectives on important issues facing today’s cancer care professionals. One variation of the program, titled, 

, comprises live virtual or on-site premium reporting for oncologists as it covers the latest news and information coming out of the largest annual oncology conferences. 

The Evolving Role of ctDNA Testing in Colorectal Cancer

The University of Texas MD Anderson Cancer Center

Cancer Centers

Partner

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss how ctDNA assays have improved MRD detection in CRC.